Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Taiwan Liposome Plans to Stage $50 Million IPO in the US

publication date: Feb 20, 2018

Taiwan Liposome, a company developing extended-release delivery of known drugs, has filed for a $50 million IPO on the NASDAQ exchange. The company is already listed in Taiwan, where it has a market capitalization of $198 million. TLC has a portfolio of four candidates in clinical development in Taiwan, China and the US. Last month, TWC formed a Hong Kong JV with Jixi Pharma that will market TLC's drugs in China. Jixi invested $20 million for a minority stake in the JV and will add up to $130 million to support the JV's operations. More details....

Stock Symbol: (TW: 4152)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.